• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788

    ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788

  2. The Medicines Company Appoints Alexander J. Denner, Ph.D. to its Board of Directors

    The Medicines Company Appoints Alexander J. Denner, Ph.D. to its Board of Directors

  3. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 - Research and Markets

    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 - Research and Markets

  4. ARIAD Reports Inducement Grant to New Chief Executive Officer

    ARIAD Reports Inducement Grant to New Chief Executive Officer

  5. ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors

    ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors

  6. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.